Tieshan Wang,Wei Wang,Siying Zhu,Minsi Zhou,Peng Li,Jing Wu,Shutian Zhang,Haiyun Shi
{"title":"用于检测粪便钙粘蛋白的颗粒增强比浊免疫分析法(PETIA)的临床性能。","authors":"Tieshan Wang,Wei Wang,Siying Zhu,Minsi Zhou,Peng Li,Jing Wu,Shutian Zhang,Haiyun Shi","doi":"10.1080/00365513.2024.2403006","DOIUrl":null,"url":null,"abstract":"Particle-enhanced turbidimetric immunoassay (PETIA) is a new measurement procedure for detecting fecal calprotectin (FC). We aimed to investigate the accuracy and clinical performance of PETIA for FC. We assessed the accuracy of PETIA for FC measurements through concordance analysis, Passing-Bablok regression and Bland-Altman analysis, using enzyme-linked immunosorbent assay (ELISA) as the reference. To evaluate the clinical performance of PETIA, the FC levels of individuals with significant and non-significant bowel diseases were compared. The receiver operating characteristic (ROC) analysis was performed to determine the appropriate cut-off value of FC detected by PETIA for discriminating subjects with significant and non-significant colorectal lesions. Of the 413 cases analyzed, 340 (82.3%) were concordant between PETIA and ELISA. No significant discordance was observed. There was a good agreement (y = -7.710+0.957x) between PETIA and ELISA for detecting FC. The FC level detected by PETIA in patients with significant bowel diseases (159.1 [31.3, 821.0] µg/g) was significantly higher than that of subjects with non-significant bowel diseases (10.3 [4.2, 38.5] µg/g) (p < 0.001). The AUC of FC for identifying significant bowel diseases detected by PETIA was 0.82 (p < 0.001). With a cut-off value of 77.6µg/g, the specificity and positive predictive value were 92.2% and 97.1%, respectively. The PETIA for FC measurement showed good clinical performance for detecting bowel diseases.","PeriodicalId":501634,"journal":{"name":"Scandinavian Journal of Clinical and Laboratory Investigation","volume":"7 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical performance of a particle enhanced turbidimetric immunoassay (PETIA) for detecting fecal calprotectin.\",\"authors\":\"Tieshan Wang,Wei Wang,Siying Zhu,Minsi Zhou,Peng Li,Jing Wu,Shutian Zhang,Haiyun Shi\",\"doi\":\"10.1080/00365513.2024.2403006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Particle-enhanced turbidimetric immunoassay (PETIA) is a new measurement procedure for detecting fecal calprotectin (FC). We aimed to investigate the accuracy and clinical performance of PETIA for FC. We assessed the accuracy of PETIA for FC measurements through concordance analysis, Passing-Bablok regression and Bland-Altman analysis, using enzyme-linked immunosorbent assay (ELISA) as the reference. To evaluate the clinical performance of PETIA, the FC levels of individuals with significant and non-significant bowel diseases were compared. The receiver operating characteristic (ROC) analysis was performed to determine the appropriate cut-off value of FC detected by PETIA for discriminating subjects with significant and non-significant colorectal lesions. Of the 413 cases analyzed, 340 (82.3%) were concordant between PETIA and ELISA. No significant discordance was observed. There was a good agreement (y = -7.710+0.957x) between PETIA and ELISA for detecting FC. The FC level detected by PETIA in patients with significant bowel diseases (159.1 [31.3, 821.0] µg/g) was significantly higher than that of subjects with non-significant bowel diseases (10.3 [4.2, 38.5] µg/g) (p < 0.001). The AUC of FC for identifying significant bowel diseases detected by PETIA was 0.82 (p < 0.001). With a cut-off value of 77.6µg/g, the specificity and positive predictive value were 92.2% and 97.1%, respectively. The PETIA for FC measurement showed good clinical performance for detecting bowel diseases.\",\"PeriodicalId\":501634,\"journal\":{\"name\":\"Scandinavian Journal of Clinical and Laboratory Investigation\",\"volume\":\"7 1\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Clinical and Laboratory Investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/00365513.2024.2403006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Clinical and Laboratory Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/00365513.2024.2403006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
微粒增强比浊免疫分析法(PETIA)是一种检测粪便钙粘蛋白(FC)的新方法。我们旨在研究 PETIA 检测 FC 的准确性和临床表现。我们以酶联免疫吸附试验(ELISA)为参照,通过一致性分析、Passing-Bablok回归和Bland-Altman分析评估了PETIA检测FC的准确性。为了评估 PETIA 的临床表现,比较了有明显和无明显肠道疾病患者的 FC 水平。通过接收器操作特征(ROC)分析,确定了 PETIA 检测到的 FC 的适当临界值,以区分有明显和无明显结直肠病变的受试者。在分析的 413 个病例中,340 个(82.3%)病例的 PETIA 和 ELISA 检测结果一致。没有观察到明显的不一致。PETIA 和 ELISA 检测 FC 的一致性很好(y = -7.710+0.957x)。有明显肠道疾病的患者通过 PETIA 检测到的 FC 水平(159.1 [31.3, 821.0] µg/g)明显高于无明显肠道疾病的受试者(10.3 [4.2, 38.5] µg/g)(p < 0.001)。通过 PETIA 检测出明显肠道疾病的 FC AUC 为 0.82(p < 0.001)。以 77.6µg/g 为临界值,特异性和阳性预测值分别为 92.2% 和 97.1%。用于 FC 测量的 PETIA 在检测肠道疾病方面表现出良好的临床性能。
Clinical performance of a particle enhanced turbidimetric immunoassay (PETIA) for detecting fecal calprotectin.
Particle-enhanced turbidimetric immunoassay (PETIA) is a new measurement procedure for detecting fecal calprotectin (FC). We aimed to investigate the accuracy and clinical performance of PETIA for FC. We assessed the accuracy of PETIA for FC measurements through concordance analysis, Passing-Bablok regression and Bland-Altman analysis, using enzyme-linked immunosorbent assay (ELISA) as the reference. To evaluate the clinical performance of PETIA, the FC levels of individuals with significant and non-significant bowel diseases were compared. The receiver operating characteristic (ROC) analysis was performed to determine the appropriate cut-off value of FC detected by PETIA for discriminating subjects with significant and non-significant colorectal lesions. Of the 413 cases analyzed, 340 (82.3%) were concordant between PETIA and ELISA. No significant discordance was observed. There was a good agreement (y = -7.710+0.957x) between PETIA and ELISA for detecting FC. The FC level detected by PETIA in patients with significant bowel diseases (159.1 [31.3, 821.0] µg/g) was significantly higher than that of subjects with non-significant bowel diseases (10.3 [4.2, 38.5] µg/g) (p < 0.001). The AUC of FC for identifying significant bowel diseases detected by PETIA was 0.82 (p < 0.001). With a cut-off value of 77.6µg/g, the specificity and positive predictive value were 92.2% and 97.1%, respectively. The PETIA for FC measurement showed good clinical performance for detecting bowel diseases.